Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action

Neuroscience Letters

Volumn 506, Issue 2, 2012, Pages 175-179

  Zhu, Ting Ge ^a   Wang, Xiao Xia ^a   Luo, Wei Feng ^a   Zhang, Qi Lin ^a   Huang, Ting Ting ^a   Xu, Xing Shun ^a   Liu, Chun Feng ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

6 Hydroxydopamine (6 OHDA); Oxidative stress; Parkinson's disease; Urate

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; OXIDOPAMINE; SUPEROXIDE DISMUTASE; URATE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK REDUCTION; URIC ACID BLOOD LEVEL;

ADRENERGIC AGENTS; ANIMALS; ANTIOXIDANTS; NEURONS; OXIDATIVE STRESS; OXIDOPAMINE; PC12 CELLS; RATS; URIC ACID;

EID: 84655161553     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.10.075     Document Type: Article

References (28)

1. Allen R.G., Tresini M. Oxidative stress and gene regulation. Free Radic. Biol. Med. 2000, 28:463-499.
2. Alonso A., Rodriguez L.A., Logroscino G., Hernan M.A. Gout and risk of Parkinson disease: a prospective study. Neurology 2007, 69:1696-1700.
3. Alonso A., Sovell K.A. Gout, hyperuricemia, and Parkinson's disease: a protective effect?. Curr. Rheumatol. Rep. 2010, 12:149-155.
4. Alvarez-Fischer D., Guerreiro S., Hunot S., Saurini F., Marien M., Sokoloff P., Hirsch E.C., Hartmann A., Michel P.P. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J. Neurochem. 2008, 107:701-711.
5. Andreadou E., Nikolaou C., Gournaras F., Rentzos M., Boufidou F., Tsoutsou A., Zournas C., Zissimopoulos V., Vassilopoulos D. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 2009, 111:724-728.
6. Annanmaki T., Muuronen A., Murros K. Low plasma uric acid level in Parkinson's disease. Mov. Disord. 2007, 22:1133-1137.
7. Arimoto T., Yoshikawa T., Takano H., Kohno M. Generation of reactive oxygen species and 8-hydroxy-2'-deoxyguanosine formation from diesel exhaust particle components in L1210 cells. Jpn. J. Pharmacol. 1999, 80:49-54.
8. Church W.H., Ward V.L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 1994, 33:419-425.
9. Davies K.J., Sevanian A., Muakkassah-Kelly S.F., Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem. J 1986, 235:747-754.
10. de Lau L.M., Koudstaal P.J., Hofman A., Breteler M.M. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 2005, 58:797-800.
11. Drechsel D.A., Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic. Biol. Med. 2008, 44:1873-1886.
12. Gao X., Chen H., Choi H.K., Curhan G., Schwarzschild M.A., Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am. J. Epidemiol. 2008, 167:831-838.
13. Guerreiro S., Ponceau A., Toulorge D., Martin E., Alvarez-Fischer D., Hirsch E.C., Michel P.P. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J. Neurochem. 2009, 109:1118-1128.
14. Haberman F., Tang S.C., Arumugam T.V., Hyun D.H., Yu Q.S., Cutler R.G., Guo Z., Holloway H.W., Greig N.H., Mattson M.P. Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neuromolecular Med. 2007, 9:315-323.
15. Hanrott K., Gudmunsen L., O'Neill M.J., Wonnacott S. 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 2006, 281:5373-5382.
16. Inoue S., Kawanishi S. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett. 1995, 371:86-88.
17. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994, 344:796-798.
18. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl 3):S26-S36. (discussion S36-28).
19. Kikuchi Y., Yasuhara T., Agari T., Kondo A., Kuramoto S., Kameda M., Kadota T., Baba T., Tajiri N., Wang F., Tayra J.T., Liang H., Miyoshi Y., Borlongan C.V., Date I. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. J. Cell. Physiol. 2011, 226:1390-1398.
20. Miller R.L., James-Kracke M., Sun G.Y., Sun A.Y. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem. Res. 2009, 34:55-65.
21. Muraoka S., Miura T. Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol. Toxicol. 2003, 93:284-289.
22. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87:315-424.
23. Rodriguez-Blanco J., Martin V., Herrera F., Garcia-Santos G., Antolin I., Rodriguez C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J. Neurochem. 2008, 107:127-140.
24. Schulz J.B., Matthews R.T., Muqit M.M., Browne S.E., Beal M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 1995, 64:936-939.
25. Wang L.J., Luo W.F., Wang H.H., Ni G.H., Ye Y., Li D., Liu C.F. Protective effects of uric acid on nigrostriatal system injury induced by 6-hydroxydopamine in rats. Zhonghua Yi Xue Za Zhi 2010, 90:1362-1365.
26. Weisskopf M.G., O'Reilly E., Chen H., Schwarzschild M.A., Ascherio A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 2007, 166:561-567.
27. Winquist A., Steenland K., Shankar A. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov. Disord. 2010, 25:932-936.
28. Yasuhara T., Hara K., Sethi K.D., Morgan J.C., Borlongan C.V. Increased 8-OHdG levels in the urine, serum, and substantia nigra of hemiparkinsonian rats. Brain Res. 2007, 1133:49-52.